Equities News Equities News
Equity Market News 19th May 2012

Equity Org Headlines:

Essar Energy adds 3 percent in mostly lower London energy sector

Antofagasta leads miners higher in London

Hunting plc leads energy sector lower

Sports Direct International leads London retailers higher

Pace plc drops 40 percent on profits warning

Royal Bank of Scotland leads London banks lower

Royal Bank of Scotland leads banks, FTSE 100 higher in London

Lloyds Banking Group drops 8 percent on first-quarter loss

Lloyds shares down on PPI claims

Aquarius Platinum adds 7 percent amid mostly lower mining sector

09/08/05

Permalink 07:13:12 am, Categories: Europe Eurofirst, Sectors, Finance, Pharmaceuticals, Energy & Power, Oil, 216 words  

Oil sector helps push European equities

In Europe on Tuesday, the FTSE Eurofirst 300 closed 0.7 percent higher at 1,189.21.

Gains in the oil sector did a great deal to help, as did the news that French utility Suez was poised to purchase all the stock of Electrabel, the Belgian electricity supplier, that id does not already own.

Shares in Suez were up 7 percent to €23.54, while Electrabel gained 6.7 percent on the news, to €415.70.

In the oil sector, OMV was up 3.6 percent to €40, Neste Oil gained 3.4 percent to €23.90, and Total rose 1.3 percent to €211.40.

The financial sector was mixed. Swiss bank UBS lost 1.4 percent to SFr104.40 on net profits that were somewhat below predictions. Swiss reinsurer Converium was down 0.4 percent to Sfr11.95 after releasing a second quarter report which showed that while net profits were up, its underwriting division had suffered a loss.

Deutsche Borse, which operates the Frankfurt Stock Exchange, was up 2.8 percent to €73.72 on record profits in the second quarter. As a result, year-long earnings estimates were raised.

Meanwhile, in the pharmaceuticals sector, Irish drug maker Elan gained 19.7 percent on the day to €7.30 after the release of a study that showed no new cases of the brain disease that caused it to have to remove its multiple sclerosis drug Tysabri from the market in February. That withdrawal caused Elan’s shares to fall by 90 percent.

Permalink